Advancing Alzheimer's Research: enhancing clinical trial diversity and relevant imaging considerations

We cannot play this video. The video is embedded from YouTube, your current cookie preferences do not allow the storing of some of the cookies the player will place.

This webinar has now concluded and will be available on demand soon

Advancing Alzheimer's Research: enhancing clinical trial diversity and relevant imaging considerations

Improving the recruitment rate of traditionally underrepresented populations in AD research is a key consideration for sponsors designing AD clinical trials. This webinar provides an overview on associated challenges for AD trial design and looks at some of the approaches that can be implemented to increase recruitment rates. The webinar furthermore looks at implications and open questions on various biomarkers, in particular amyloid PET imaging.


  • Richard Mohs, Chief Science Officer – Global Alzheimer’s Platform Foundation
  • Robin Wolz, Chief Scientific Officer - IXICO

What You'll Learn:

Diversity in Clinical Trials:

  • Inclusive Research: Understand the importance of recruiting diverse participants in clinical trials. The Bio-Hermes study emphasizes including underrepresented groups, such as Black and Non-white Hispanic populations, who are disproportionately affected by AD.
  • Equity in Healthcare: Learn how this inclusive approach not only ensures broader applicability of research findings but also moves us closer to equitable healthcare solutions.


  • Biomarker interpretation: Use of PET imaging biomarkers for amyloid and tau has become an integral part of AD clinical trials. Learn about the interpretation of imaging biomarkers in multi-center clinical trials and how they can be used to characterize diverse subject populations.

Join experts Richard Mohs and Robin Wolz as they guide us through these groundbreaking topics, offering their extensive knowledge and answering your questions.

This webinar is a unique opportunity to understand how the latest research is paving the way for more effective and inclusive Alzheimer’s disease management. By incorporating these findings into future clinical trial designs now, we can accelerate the development of treatments that benefit everyone.

About the speakers

Richard Mohs, Chief Science Officer – Global Alzheimer’s Platform Foundation
Richard worked at Eli Lilly and Company in several leadership positions including Vice President for Neuroscience Early Clinical Development and Leader of the Global Alzheimer’s Drug Development team. He spent 23 years with the Mount Sinai School of Medicine as a Professor in the Department of Psychiatry and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Center.

Richard is the author or co-author of over 350 scientific papers, is a consultant to several academic institutions, is a member of the Board of Governors for the Alzheimer’s Drug Discovery Foundation (ADDF) and is a member of the Board of Directors of the Greater Indiana Chapter of the Alzheimer’s Association. He received a PhD in psychology from Stanford University and completed postdoctoral training in Pharmacology at the Stanford Medical School.

Robin Wolz, Chief Scientific Officer - IXICO

Robin has over 15 years of experience in the development of innovative analytics solutions in healthcare with a focus on imaging technology. Prior to IXICO, Robin held different roles at Philips in the Research and Diagnostic X-Ray divisions.

Robin holds a PhD in medical imaging and computer science from Imperial College London, focused on early detection of Alzheimer's disease. He is the co-author of more than 100 publications and holds multiple patents in the field of medical imaging and AI data analytics.


Date: 29/05/2024